Randomized Controlled Trials in Neuroendocrine Tumors

Understanding of neuroendocrine tumors has increased greatly in the last 2 decades. Along with this, the prevalence of neuroendocrine tumors has increased because of the ubiquitous use of cross-sectional imaging, improved endoscopic screening, and the indolent nature of the disease. Up to 35% of patients have symptoms at the time of diagnosis, whereas the others have occult disease. Neuroendocrine tumors are a diverse group of malignancies with unique clinical courses. This article critically reviews the most important randomized controlled trials for neuroendocrine tumors and introduces a few awaiting completion.